INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
  • Age: Between 18 - 99 Years
  • Gender: Male
  • Other Inclusion Criteria:
    1) Histologically confirmed prostate adenocarcinoma by biopsy within 1 year (365 days) from registration. The most recent biopsy will determine eligibility. 2) Successful acquisition of a genomic classifier Decipher score (Decipher Biosciences, Vancouver, BC) from archived tissue. Patients who already have a Decipher score must present official documentation of the report. 3) Able to undergo radiation therapy with curative intent.

You may not be eligible for this study if the following are true:

  • 1) Acute toxicities of prior treatments and procedures not resolved to grade 1 at baseline before randomization. 2) Prior surgical, cryotherapy, or high-intensity focused ultrasound for prostate cancer. 3) Prior orchiectomy or hormonal therapy (GnRH agonists, NSAA).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.